Mette Thomsen
Overview
Explore the profile of Mette Thomsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al.
Diabetes Obes Metab
. 2021 Sep;
24(1):94-105.
PMID: 34514682
Aim: We evaluated gastrointestinal (GI) adverse events (AEs) with once-weekly semaglutide 2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL). Materials And Methods: AE...
2.
Granhall C, Baekdal T, Breitschaft A, Sondergaard F, Anderson T, Thomsen M
Diabetes Ther
. 2021 Jul;
12(9):2599-2610.
PMID: 34319564
Introduction: Oral delivery of proteins, including glucagon-like peptide 1 (GLP-1) receptor agonists, is impeded by low gastrointestinal permeation. Oral semaglutide has been developed for once-daily oral administration by co-formulation of...
3.
Elameen A, Kosman V, Thomsen M, Pozharitskaya O, Shikov A
Molecules
. 2020 Aug;
25(15).
PMID: 32751483
L. (roseroot) is an adaptogen plant belonging to the Crassulaceae family. The broad spectrum of biological activity of is attributed to its major phenyletanes and phenylpropanoids: rosavin, salidroside, rosin, cinnamyl...
4.
Kushner R, Calanna S, Davies M, Dicker D, Garvey W, Goldman B, et al.
Obesity (Silver Spring)
. 2020 May;
28(6):1050-1061.
PMID: 32441473
Objective: The obesity epidemic is a public health concern, warranting further research into pharmacological treatments for weight management (WM) as an adjunct to lifestyle interventions. The Semaglutide Treatment Effect in...
5.
Husain M, Birkenfeld A, Donsmark M, Dungan K, Eliaschewitz F, Franco D, et al.
N Engl J Med
. 2019 Jun;
381(9):841-851.
PMID: 31185157
Background: Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are...
6.
Baekdal T, Borregaard J, Hansen C, Thomsen M, Anderson T
Clin Pharmacokinet
. 2019 Apr;
58(9):1193-1203.
PMID: 30945118
Background: Oral semaglutide is a tablet co-formulation of the human glucagon-like peptide-1 (GLP-1) analog semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The absorption of coadministered oral drugs...
7.
Granhall C, Donsmark M, Blicher T, Golor G, Sondergaard F, Thomsen M, et al.
Clin Pharmacokinet
. 2018 Dec;
58(6):781-791.
PMID: 30565096
Background: Oral semaglutide is a novel tablet containing the human glucagon-like peptide-1 (GLP‑1) analogue semaglutide, co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The safety and pharmacokinetics of...
8.
Bain S, Mosenzon O, Arechavaleta R, Bogdanski P, Comlekci A, Consoli A, et al.
Diabetes Obes Metab
. 2018 Oct;
21(3):499-508.
PMID: 30284349
Aims: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon-like peptide-1 receptor agonist. Materials And Methods: PIONEER 6 is a multinational, randomized, placebo-controlled,...
9.
Baekdal T, Thomsen M, Kupcova V, Hansen C, Anderson T
J Clin Pharmacol
. 2018 Apr;
58(10):1314-1323.
PMID: 29693715
Semaglutide is a human glucagon-like peptide-1 analog that has been co-formulated with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, for oral administration. This trial (NCT02016911) investigated whether hepatic impairment affects...
10.
Granhall C, Sondergaard F, Thomsen M, Anderson T
Clin Pharmacokinet
. 2018 Apr;
57(12):1571-1580.
PMID: 29623579
Background: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) as a tablet for oral administration. This trial (NCT02014259) investigated the...